We thank Dr. Gejerman for recognizing the importance of this work. Indeed, we agree
that the results of the present study are hypothesis generating. Thus, we enthusiastically
await the long-term results of RTOG0815 which, with a planned enrollment of 1520 men
with intermediate-risk prostate cancer, randomized men to either dose-escalated RT
alone vs dose-escalated RT combined with 6 months of androgen deprivation, stratified
by the number of risk factors, ACE-27, Adult Comorbidity Evaluation 27 comorbidity
status, and RT modality. These data will validate or refute the hypothesis-generating
finding in the present study, which suggests that a higher prostate-specific antigen
nadir and shorter time to prostate-specific antigen nadir are prognostic factors and
potential surrogates for prostate cancer-specific mortality, in a population treated
with dose-escalated RT.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to UrologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
November 20,
2018
Received:
September 24,
2018
Identification
Copyright
© 2019 Published by Elsevier Inc.
